Brief: Abionyx: First Patient Enrolled In Phase 2A Clinical Study With CER-001

Abionyx Pharma SA

08/06/2021 06:35

June 8 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2A
CLINICAL
STUDY WITH CER-001, THE BIO-HDL FOR THE TREATMENT OF SEPTIC
PATIENTS AT HIGH RISK OF DEVELOPING ACUTE KIDNEY INJURY
    * EVALUATION OF CLINICAL ACTIVITY BY DOSAGE LEVEL OF CER-001
IN
PREVENTION OF ACUTE KIDNEY INJURY IN ICU PATIENTS WITH
SEPTICEMIA
    * POTENTIALLY MODIFYING EFFECT ON PROGRESSION OF
INFLAMMATORY
CASCADE IN SEPSIS

Source text for Eikon:  ID:nBw34q0hGa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))